A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.

OBJECTIVE: To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. METHODS: We reviewed CV outcomes during the long-term followup of patients in th...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Suppiah, R, Judge, A, Batra, R, Flossmann, O, Harper, L, Höglund, P, Javaid, M, Jayne, D, Mukhtyar, C, Westman, K, Davis, J, Hoffman, G, McCune, W, Merkel, P, St Clair, E, Seo, P, Spiera, R, Stone, J, Luqmani, R
Formaat: Journal article
Taal:English
Gepubliceerd in: 2011
_version_ 1826272554345562112
author Suppiah, R
Judge, A
Batra, R
Flossmann, O
Harper, L
Höglund, P
Javaid, M
Jayne, D
Mukhtyar, C
Westman, K
Davis, J
Hoffman, G
McCune, W
Merkel, P
St Clair, E
Seo, P
Spiera, R
Stone, J
Luqmani, R
author_facet Suppiah, R
Judge, A
Batra, R
Flossmann, O
Harper, L
Höglund, P
Javaid, M
Jayne, D
Mukhtyar, C
Westman, K
Davis, J
Hoffman, G
McCune, W
Merkel, P
St Clair, E
Seo, P
Spiera, R
Stone, J
Luqmani, R
author_sort Suppiah, R
collection OXFORD
description OBJECTIVE: To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. METHODS: We reviewed CV outcomes during the long-term followup of patients in the first 4 European Vasculitis Study Group (EUVAS) trials of WG and MPA. CV events were defined as CV death, stroke, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention. Logistic regression was performed to create a model to predict the absolute risk of a CV event. The model was tested using the Wegener's Granulomatosis Etanercept Trial (WGET) cohort. RESULTS: Seventy-four (13.8%) of 535 patients with 5 years of followup from the EUVAS trials had at least 1 CV event: 33 (11.7%) of 281 WG versus 41 (16.1%) of 254 MPA. The independent determinants of CV outcomes were older age (odds ratio [OR] 1.45, 95% confidence interval [95% CI] 1.11-1.90), diastolic hypertension (OR 1.97, 95% CI 0.98-3.95), and positive proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) status (OR 0.39, 95% CI 0.20-0.74). The model was validated using the WGET cohort (area under the receiver operating characteristic curve of 0.80). CONCLUSION: Within 5 years of diagnosis of WG or MPA, 14% of patients will have a CV event. We have constructed and validated a tool to quantify the risk of a CV event based on age, diastolic hypertension, and PR3 ANCA status in patients without prior CV disease. In patients with vasculitis, PR3 ANCA is associated with a reduced CV risk compared to myeloperoxidase ANCA or negative ANCA status.
first_indexed 2024-03-06T22:14:23Z
format Journal article
id oxford-uuid:52e781d3-5d33-44e9-b24c-3910f7d68fbe
institution University of Oxford
language English
last_indexed 2024-03-06T22:14:23Z
publishDate 2011
record_format dspace
spelling oxford-uuid:52e781d3-5d33-44e9-b24c-3910f7d68fbe2022-03-26T16:28:23ZA model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:52e781d3-5d33-44e9-b24c-3910f7d68fbeEnglishSymplectic Elements at Oxford2011Suppiah, RJudge, ABatra, RFlossmann, OHarper, LHöglund, PJavaid, MJayne, DMukhtyar, CWestman, KDavis, JHoffman, GMcCune, WMerkel, PSt Clair, ESeo, PSpiera, RStone, JLuqmani, ROBJECTIVE: To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. METHODS: We reviewed CV outcomes during the long-term followup of patients in the first 4 European Vasculitis Study Group (EUVAS) trials of WG and MPA. CV events were defined as CV death, stroke, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention. Logistic regression was performed to create a model to predict the absolute risk of a CV event. The model was tested using the Wegener's Granulomatosis Etanercept Trial (WGET) cohort. RESULTS: Seventy-four (13.8%) of 535 patients with 5 years of followup from the EUVAS trials had at least 1 CV event: 33 (11.7%) of 281 WG versus 41 (16.1%) of 254 MPA. The independent determinants of CV outcomes were older age (odds ratio [OR] 1.45, 95% confidence interval [95% CI] 1.11-1.90), diastolic hypertension (OR 1.97, 95% CI 0.98-3.95), and positive proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) status (OR 0.39, 95% CI 0.20-0.74). The model was validated using the WGET cohort (area under the receiver operating characteristic curve of 0.80). CONCLUSION: Within 5 years of diagnosis of WG or MPA, 14% of patients will have a CV event. We have constructed and validated a tool to quantify the risk of a CV event based on age, diastolic hypertension, and PR3 ANCA status in patients without prior CV disease. In patients with vasculitis, PR3 ANCA is associated with a reduced CV risk compared to myeloperoxidase ANCA or negative ANCA status.
spellingShingle Suppiah, R
Judge, A
Batra, R
Flossmann, O
Harper, L
Höglund, P
Javaid, M
Jayne, D
Mukhtyar, C
Westman, K
Davis, J
Hoffman, G
McCune, W
Merkel, P
St Clair, E
Seo, P
Spiera, R
Stone, J
Luqmani, R
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
title A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
title_full A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
title_fullStr A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
title_full_unstemmed A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
title_short A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
title_sort model to predict cardiovascular events in patients with newly diagnosed wegener s granulomatosis and microscopic polyangiitis
work_keys_str_mv AT suppiahr amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT judgea amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT batrar amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT flossmanno amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT harperl amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT hoglundp amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT javaidm amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT jayned amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT mukhtyarc amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT westmank amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT davisj amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT hoffmang amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT mccunew amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT merkelp amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT stclaire amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT seop amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT spierar amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT stonej amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT luqmanir amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT suppiahr modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT judgea modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT batrar modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT flossmanno modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT harperl modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT hoglundp modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT javaidm modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT jayned modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT mukhtyarc modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT westmank modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT davisj modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT hoffmang modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT mccunew modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT merkelp modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT stclaire modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT seop modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT spierar modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT stonej modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis
AT luqmanir modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis